Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,903.00GBp
9:40pm IST
Change (% chg)

85.00 (+4.68%)
Prev Close
1,818.00
Open
1,833.50
Day's High
1,919.00
Day's Low
1,820.20
Volume
798,476
Avg. Vol
547,005
52-wk High
1,919.00
52-wk Low
814.20

Chart for

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.34
Market Cap(Mil.): £2,897.33
Shares Outstanding(Mil.): 240.65
Dividend: 8.50
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 22.78 30.93 32.76
EPS (TTM): 0.53 -- --
ROI: 4.67 15.07 14.61
ROE: 6.88 16.59 16.33

Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

LONDON London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients.

18 Jul 2018

Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

LONDON, July 18 London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients.

18 Jul 2018

GSK wins new reprieve as Hikma's generic Advair delayed again

GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.

12 Mar 2018

BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus

* HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE'S ADVAIR DISKUS

12 Mar 2018

Hikma plans new clinical study over generic Advair

March 12 Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.

12 Mar 2018

Earnings vs. Estimates